[Translation] An open-label, multicenter, multi-cohort Phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of HYP-2090PTSA in patients with KRAS-mutated advanced solid tumors
剂量递增主要目的:评价HYP-2090PTSA在KRAS突变的晚期实体瘤患者中的安全性和耐受性;确定HYP-2090PTSA推荐II期剂量(RP2D)和/或最大耐受剂量(MTD)。剂量扩展主要目的:评价HYP-2090PTSA在KRAS G12C突变的晚期实体瘤患者中的有效性。
[Translation] The main purpose of dose escalation is to evaluate the safety and tolerability of HYP-2090PTSA in patients with KRAS-mutated advanced solid tumors; to determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) of HYP-2090PTSA. The primary purpose of the dose expansion is to evaluate the effectiveness of HYP-2090PTSA in patients with KRAS G12C mutated advanced solid tumors.